Investigating the Effect of Micardis® on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients - Tabular View

Tracking Information

First Received Date ^ICMJE

April 9, 2009

Last Updated Date

March 2, 2010

Start Date ^ICMJE

April 2009

Primary Completion Date

January 2010 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

collect significant data on powerful BP reduction of Telmisartan in the context of 24h BP reduction after a 6 to 8 week treatment period [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Original Primary Outcome Measures ^ICMJE

collect significant data on powerfull BP reduction of Telmisartan in the context of 24h BP reduction after a 6 to 8 week treatment period [ Time Frame: 8 weeks ]

Change History

Complete list of historical versions of study NCT00879411 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

drug safety, efficacy and tolerability of Telmisartan [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Original Secondary Outcome Measures ^ICMJE

drug safety, efficacy and tolerability of Telmisartan [ Time Frame: 8 weeks ]

Descriptive Information

Brief Title ^ICMJE

Investigating the Effect of Micardis® on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

Official Title ^ICMJE

24h BP Under Micardis in Daily Practice

Brief Summary

Practical experience report (PER) investigating the effect of Micardis® on the average 24h blood pressure of therapy-naive and therapy-experienced patients

Detailed Description

Study Phase

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Observational Model: Case-Only
Time Perspective: Prospective

Condition ^ICMJE

Hypertension

Intervention ^ICMJE

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

Primary Completion Date

January 2010 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Patients who have recently been diagnosed with hypertension
Patients whose current blood pressure treatment are inadequate and needs to be revised are suitable for inclusion.

Exclusion Criteria:

None (according to investigator)

Gender

Both

Ages

18 Years to 95 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Switzerland

Administrative Information

NCT ID ^ICMJE

NCT00879411

Responsible Party

Boehringer Ingelheim, Study Chair, Boehringer Ingelheim

Study ID Numbers ^ICMJE

502.582

Study Sponsor ^ICMJE

Boehringer Ingelheim Pharmaceuticals

Collaborators ^ICMJE

Investigators ^ICMJE

Study Chair:

Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals

Information Provided By

Boehringer Ingelheim Pharmaceuticals

Verification Date

March 2010

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP